Electrical Coupling Information From The Rhythmia HDx System And DirectSense Technology In Subjects With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation Clinical Trial

— LOCALIZE  

Official title:

ELectrical COupling Information From The Rhythmia HDx Mapping System And DireCtSense Technology In The Treatment Of Paroxysmal AtriaL FibrIllation- A Non-RandomiZed, ProspEctive Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03232645
• Other study ID #: PM007
• Status: Completed
• Phase: N/A
• Start date: January 8, 2018
• Est. completion date: August 5, 2020

Study information

• Verified date: August 2021
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to collect data on the use of the Rhythmia HDx mapping system running commercially available Software Version 2.0 or any future commercially available Software Version with DirectSense technology and the IntellaMap OrionTM mapping catheter in patients indicated for ablation treatment for de-novo Paroxysmal Atrial Fibrillation (PAF). The study will collect specific information to characterize the DirectSense technology in subjects undergoing catheter-based endocardial mapping and ablation for de-novo PAF using a commercial Rhythmia HDx mapping system. The clinical local impedance data will be used in order to generate usage guidance on the DirectSense local impedance feature in the management of de-novo PAF cases requiring Pulmonary Vein Isolation (PVI) and in order to further develop a future lesion indexing feature.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: August 5, 2020
• Est. primary completion date: June 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• • History of recurrent symptomatic PAF with =1 episode reported and documented within the 365 days prior to enrollment; PAF is defined as AF episodes that last =30 seconds in duration and terminate within 7 days.

• Refractory or intolerant to at least one Beta Blocker, Calcium Channel Blocker, Class I OR Class III anti-arrhythmic drug (AAD);

• Eligible for an ablation procedure with the Rhythmia HDx mapping system (software version 2.0 or any future commercially available Software Version), IntellaMap Orion mapping catheter and IntellaNav MiFi OI ablation catheter according to current international and local guidelines (and future revisions) and per physician discretion;

• Subjects who are willing and capable of providing informed consent;

• Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center;

• Age 18 to 80

Exclusion Criteria:

• • Diagnosed with any of the following heart conditions within 90 days (3 months) prior to enrollment:

1. New York Heart Association (NYHA) Class III or IV

2. Left ventricular ejection fraction (LVEF) <35%

3. Left atrial (LA) diameter >5.5 cm

4. Unstable angina or ongoing myocardial ischemia (OMI)

5. Transmural myocardial infarction (MI), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery

• Active systemic infection or sepsis;

• Undergone any left atrial heart ablation procedure, either surgical or catheter ablation

• Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route

• Subject has a Left Atrial Appendage Closure (LAAC) or Percutaneous Transcatheter Closure of a Patent Foramen Ovale (PFO)

• Subject has persistent or long-standing persistent atrial fibrillation (AF) ( >1 AF episodes lasting greater than 7 days, with no episodes having lasted greater than 30 days, within the past year)

• Life expectancy = 6 months per physician judgment

• Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility;

• The subject is unable or not willing to complete follow-up visits and examination for the duration of the study;

• Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).

Related Conditions & MeSH terms

• Atrial Fibrillation
• Paroxysmal Atrial Fibrillation

Intervention

Device:
• Ablation procedure
Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux
Germany	Universitäres Herzzentrum Hamburg	Hamburg
Germany	Stadtisches Klinikum Karlsruhe	Karlsruhe
Spain	Clinica Universitaria de Navarra	Pamplona
United Kingdom	Freeman Hospital	Newcastle
United Kingdom	Southampton General Hospital	Southampton

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Countries where clinical trial is conducted

France,  Germany,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local Impedance and Local Impedance Change at Day Zero and PVI Gaps at the Month 3 Assessment	Association between baseline DirectSense data (Local Impedance/Local Impedance change values) per anatomical segment of the Pulmonary Veins at index ablation procedure (Day 0) and the number of ablation gaps per anatomical segment* of the Pulmonary Veins as measured at the month 3 assessment. The outcome is a comparison of local impedance metrics in block versus reconnected segments as assessed at the 3 Month procedure.; *Each PV pair is divided in 8 segments using tags placed on the left atrium geometry created with the Rhythmia system.	Day 0 and 3 months
Secondary	Local Impedance and Local Impedance Change and PVI Gaps at Day Zero	Acute isolation gaps per anatomical segment* as associated with baseline Local Impedance and Local Impedance change values at first pass encircling during the index ablation procedure (Day 0). The outcome is a comparison of local impedance metrics in block versus reconnected segments as assessed at the index procedure (Day 0).; *Each PV pair is divided in 8 segments using tags placed on the left atrium geometry created with the Rhythmia system.	Day 0
Secondary	Number of Gaps at Day Zero	At the index procedure (Day 0), a 20-minute waiting period was required prior to assessing isolation with a left atrium map created with the Rhythmia system. Number and location of gaps for each PV per segment were collected. The outcome is reported as the mean number of gaps per each PV pair.	Day 0
Secondary	Baseline Local Impedance and Local Impedance Change at Day Zero	Average baseline local impedance and local impedance change measured at the index procedure (Day 0) for ablations performed during the first encirclement of the PVs and during the touch ups ablations performed after the 20 minute wait period.	Day 0
Secondary	Maximum Number of Gaps Per PV Segment at Day Zero	At the index procedure (Day 0), a 20-minute waiting period was required prior to assessing isolation with a left atrium map created with the Rhythmia system. Number and location of gaps for each PV per segment were collected.The outcome is reported as the maximum number of gaps identified within segments for each PV pair.	Day 0
Secondary	Local Impedance in Segments With Maximum Number of Gaps at Day Zero	Local Impedance measured at the index procedure (Day 0) in different anatomical sites of the PV pairs. It is reported the average baseline local impedance in the right and left segments with the maximum number of gaps	Day 0